WOS

Permanent URI for this collectionhttps://hdl.handle.net/11443/932

Browse

Search Results

Now showing 1 - 5 of 5
  • Item
    Headache as the sole presenting symptom of cerebral venous sinuses thrombosis: Subgroup analysis of data from the VENOST study
    (KARE PUBL, 2021-01-01) Duman, Taskin; Cinar, Nilgun; Uluduz, Derya; Domac, Fusun Mayda; Ozturk, Serefnur; Yayla, Vildan; Karahan, Ali Yavuz; Afsar, Nazire; Sungur, Mehmet Ali; Goksu, Eylem Ozaydin; Yurekli, Vedat Ali; Genc, Hamit; Utku, Uygar; Sahin, Sevki; Tekeli, Hakan; Tokuc, Firdevs Ezgi; Uzuner, Nevzat; Senol, Mehmet Guney; Yilmaz, Arda; Gokce, Mustafa; Demirci, Seden; Kusbeci, Ozge Yilmaz; Uzuner, Gulnur Tekgol; Caglayan, Hale Zeynep Batur; Acikgoz, Mustafa; Kurucu, Hatice; Ozdag, Mehmet Fatih; Baybas, Sevim; Ekmekci, Hakan; Cabalar, Murat; Yaman, Mehmet; Bektas, Hesna; Kaplan, Yuksel; Goksel, Basak Karakurum; Milanlioglu, Aysel; Orken, Dilek Necioglu; Aluclu, Mehmet Ufuk; Colakoglu, Sena; Tufekci, Ahmet; Bakar, Mustafa; Nazliel, Bijen; Tascilar, Nida; Goksan, Baki; Kozak, Hasan Huseyin; Misirli, Cemile Handan; Kucukoglu, Hayriye; Midi, Ipek; Mengulluoglu, Necdet; Aytac, Emrah; Yesilot, Nilufer; Ince, Birsen; Yalin, Osman Ozgur; Gunes, Taskin; Oruc, Serdar; Demir, Serkan
    Objectives: Headache is the most common complaint in cerebral venous sinus thrombosis (CVST) and it may sometimes be the only symptom in these patients. This retrospective and prospective study was an investigation of any differences in terms of clinical risk factors, radiological findings, or prognosis in patients with CVST who presented with isolated headache (IH) and cases with other concomitant findings (non-isolated headache {[}NIH]). Methods: A total of 1144 patients from a multicenter study of cerebral venous sinus thrombosis ( VENOST study) were enrolled in this research. The demographic, biochemical, clinical, and radiological aspects of 287 IH cases and 857 NIH cases were compared. Results: There were twice as many women as men in the study group. In the IH group, when gender distribution was evaluated by age group, no statistically significant difference was found. The onset of headache was frequently subacute and chronic in the IH group, but an acute onset was more common in the NIH group. Other neurological findings were observed in 29\% of the IH group during follow-up. A previous history of deep, cerebral, or other venous thromboembolism was less common in the IH group than in the NIH group. Transverse sinus involvement was greater in the IH group, whereas sagittal sinus involvement was greater in the NIH group. The presence of a plasminogen activator inhibitor (PAI) mutation was significantly greater in the IH group. Conclusion: IH and CVST should be kept in mind if a patient has subacute or chronic headache. PAI, which has an important role in thrombolytic events, may be a risk factor in CVST. Detailed hematological investigations should be considered. Additional studies are needed.
  • Item
    The close relation of tic disorders with childhood migraine and atopic background of both children and mothers
    (WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2020-01-01) Aksu, Gulen Guler; Kutuk, Meryem Ozlem; Tufan, Ali Evren; Toros, Fevziye; Uluduz, Derya; Ozge, Aynur
    Objective: This study aimed to evaluate primary headache disorders and other causative comorbidities (e.g., epilepsy, atopic disorders, recurrent abdominal pain, motion sickness, and headache) in children with tic disorders (TDs) and their mothers. Materials and Methods: In a multi-center, cross-sectional, familial association study using case-control design, youth (between 7 and 17 years) with TDs (TD, as per Diagnostic and Statistical Manual of Mental Disorders-5 criteria) and age- and sex-matched healthy controls and their mothers were evaluated in the aspect of functional syndromes spectrum including migraine, epilepsy, atopic disorders, motion sickness, and recurrent abdominal pain. Results: Seventy-nine youth with TD and 101 controls were included. Causative comorbidities, other than epilepsy and motion sickness were more common in children with TD with an odds ratio (OR) of 2.1 (atopy) and 3.9 (food allergy). Specifically, recurrent abdominal pain and migraine were found in 36.7\% and 31.7\% of children (vs. 18.8\% and 16.8\% of controls, ORs 2.5 and 2.3, respectively). Mothers of youth with TDs also have higher rates of atopy, drug allergy and allergic dermatitis (ORs
  • Item
    Reliability and Validity of Turkish Version of Headache Impact Test (HIT-6) in Patients with Migraine
    (TURKISH NEUROPSYCHIATRY ASSOC-TURK NOROPSIKIYATRI DERNEGI, 2021-01-01) Yalinay Dikmen, Pinar; Bozdag, Mumine; Gunes, Mumin; Kosak, Seda; Tasdelen, Bahar; Uluduz, Derya; Ozge, Aynur
    Introduction: The Headache Impact Test (HIT-6) is a self-report questionnaire designed to evaluate the impact of headache on quality of life. The aim of this study is to assess reliability and validity of Turkish version of HIT-6 questionnaire in patients with migraine. Methods: A total of 114 patients with migraine were included in this multicenter, prospective, descriptive study conducted at two consecutive visits 4 weeks apart. Comprehensibility, patient-physician reliability, internal consistency, test-retest reliability and validity of the translated HIT-6 were analyzed. Results: Patients identified that HIT-6 items were ``well-understood{''} in both visit 1 (ranged from 88.6\% to 95.7\%) and visit 2 (ranged from 93.0\% to 98.2\%). A highly positive correlation (R=0.876, p<0.001) was noted between visit 1 scores related to self-administered and physician-administered HIT-6 scores. Internal consistency analyzed via Cronbachs alpha values for visit 1 and visit 2 HIT-6 scores in all patients were 0.753 (acceptable) and 0.864 (excellent), respectively. HIT-6 scores of patients (64.13 (6.20) and 62.70 (7.04), at visits 1 and 2, respectively, p=0.07) showed a moderate test-retest reliability (R=0.437, p=0.0004). The HIT-6 score positively correlated with visit 1 and visit 2 headache severity-Likert scale (R=0.451 and 0.478, respectively, p<0.001) and VAS (R=0.365 and 0.531, respectively p<0.001) scores, and with visit 2 headache days for a month (R=0.215, p=0.022). Conclusion: These results demonstrated that the Turkish translation is equivalent to English version of HIT-6 in terms of internal consistency and it has moderate test-retest reliability and validity as correlated with headache severity, VAS and headache days for a month.
  • Item
    The effect of migraine and motion sickness on symptoms evoked by the caloric vestibular test
    (IOS PRESS, 2022-01-01) Gedik-Soyuyuce, Ozlem; Yalinay-Dikmen, Pinar; Korkut, Nazim
    BACKGROUND: The caloric vestibular test (CVT) may evoke headache and vestibular symptoms in susceptible people. Patients with migraines have higher susceptibility to motion sickness. In migraines, impaired habituation to repetitive stimuli is a well-known interictal abnormality. OBJECTIVE: This study is aimed at evaluating CVT-evoked headache, nausea, vomiting, and imbalance in patients with and without migraine and/or motion sickness. METHODS: A retrospective data analysis was performed on 554 patients with a complaint of dizziness who underwent bithermal CVT at a tertiary referral center. The occurrences of CVT-evoked headache, nausea, vomiting, and imbalance were observed in four groups: patients with only migraine (MG
  • Item
    Botulinum Toxin in Migraine Treatment
    (TURKISH NEUROPSYCHIATRY ASSOC-TURK NOROPSIKIYATRI DERNEGI, 2013-01-01) Aydinlar, Elif Ilgaz; Dikmen, Pinar Yalinay; Kocaman, Ayse Sagduyu
    Since botulinum toxin might have a therapeutic effect on pain, many studies investigating the efficiency of botulinum toxin in headache treatment have been done. The most satisfying results were achieved by botulinum toxin type A (BoNT/A) in the treatment of chronic migraine. In this paper, we reviewed the clinical effectiveness of BoNT/A in migraine and included our clinical experience. In our ongoing pilot study, where we have repeated BoNT/A injections every 12 weeks, The difference in the Migraine Disability Assessment (MIDAS) scores between the first and the second injections was 61.1\%